You just read:

HEC TaiGen Initiates Phase III Trial of Combination of Furaprevir and Yimitasvir for the Treatment of Chronic Hepatitis C Patients in China

News provided by

TaiGen Biotechnology

Apr 23, 2019, 03:58 ET